/EOLS
EOLS Stock - Evolus, Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$5.72-0.78%
$0.04 (-0.78%) • Jan 13
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+214.7%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EOLS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.66 – $5.78
TARGET (TP)$18.00
STOP LOSS$5.26
RISK/REWARD1:26.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$17.12
52W Low$5.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $266.27M | $202.09M | $148.62M | $99.67M | $56.54M |
| Gross Profit | $182.30M | $140.53M | $89.77M | $56.14M | $38.24M |
| Gross Margin | 68.5% | 69.5% | 60.4% | 56.3% | 67.6% |
| Operating Income | $-34,411,000 | $-49,233,000 | $-65,330,000 | $-44,405,000 | $-153,068,000 |
| Net Income | $-50,420,000 | $-61,685,000 | $-74,412,000 | $-46,810,000 | $-163,013,000 |
| Net Margin | -18.9% | -30.5% | -50.1% | -47.0% | -288.3% |
| EPS | $-0.81 | $-1.08 | $-1.33 | $-0.94 | $-4.83 |
Company Overview
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
$16
Average Target
↑ 184.1% Upside
Now
$10
Low
$16
Average
$21
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2025 | Needham | Downgrade | Hold | - |
| April 17th 2025 | BTIG Research | Initiation | Buy | $21 |
| January 29th 2024 | Barclays | Upgrade | Overweight | $16← $10 |
| June 23rd 2022 | Needham | Initiation | Buy | $18 |
| May 12th 2022 | Barclays | Upgrade | Equal Weight | $10← $8 |
Earnings History & Surprises
EOLSBeat Rate
22%
Last 18 quarters
Avg Surprise
-40.5%
EPS vs Estimate
Beats / Misses
4/13
1 met exactly
Latest EPS
$-0.14
Q4 2025
EPS Surprise History
Q1 24
-100.0%
$-0.14vs$-0.07
Q2 24
-85.7%
$-0.13vs$-0.07
Q3 24
-23.1%
$-0.07vs$-0.06
Q4 24
-137.5%
$-0.19vs$-0.08
Q1 25
-50.0%
$0.01vs$0.02
Q2 25
-80.0%
$-0.18vs$-0.10
Q3 25
-166.7%
$-0.24vs$-0.09
Q4 25
+26.3%
$-0.14vs$-0.19
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 3, 2026 | $0.07 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.09 | $-0.24 | -166.7% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.10 | $-0.18 | -80.0% | ✗ MISS |
Q1 2025 | Mar 4, 2025 | $0.02 | $0.01 | -50.0% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.08 | $-0.19 | -137.5% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-0.06 | $-0.07 | -23.1% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.07 | $-0.13 | -85.7% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.07 | $-0.14 | -100.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.22 | $-0.22 | 0.0% | = MET |
Q2 2023 | May 9, 2023 | $-0.13 | $-0.17 | -30.8% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.14 | $-0.16 | -14.3% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.27 | $-0.32 | -18.5% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-0.24 | $-0.38 | -58.3% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.41 | $-0.27 | +34.1% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.20 | $-0.29 | -45.0% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.32 | $-0.26 | +18.8% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Latest News
Stifel Maintains Buy on Evolus, Lowers Price Target to $17
📈 PositiveBenzinga•Jan 13, 2026, 06:00 PM•Also:
HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $20 Price Target
📈 PositiveBenzinga•Jan 9, 2026, 05:35 PM
Evolus Sees Prelim. Q4 Revenue $88.6M-$90.6M
📈 PositiveBenzinga•Jan 9, 2026, 01:31 PM
Needham Reiterates Hold on Evolusto Hold
➖ NeutralBenzinga•Dec 24, 2025, 11:05 AM
Mizuho Maintains Outperform on Evolus, Lowers Price Target to $19
➖ NeutralBenzinga•Dec 2, 2025, 03:29 PM
Evolus shares are trading higher after the company beat Q3 earnings and revenue estimates.
📈 PositiveBenzinga•Nov 6, 2025, 11:22 AM
CORRECTION: Evolus Q3 Adj. EPS $(0.11) Beats $(0.17) Estimate, Sales $68.967M Beat $67.449M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 11:42 PM
Evolus shares are trading higher after the company beat Q3 earnings and revenue estimates.
📈 PositiveBenzinga•Nov 5, 2025, 10:24 PM
Evolus shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 5, 2025, 09:25 PM
Evolus Affirms FY2025 Sales Guidance of $295.000M-$305.000M vs $295.999M Est
➖ NeutralBenzinga•Nov 5, 2025, 09:21 PM
Evolus Q3 EPS $(0.24) Beats $(0.26) Estimate, Sales $68.967M Beat $67.449M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:20 PM
Watching Evolus; Hearing Zacks Under $10 Newsletter Mentions Stock As A Buy
📈 PositiveBenzinga•Nov 4, 2025, 02:55 PM
BTIG Reiterates Buy on Evolus, Maintains $18 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 03:49 PM
Evolus Appoints Tatjana Mitchell As CFO, Effective September 8, 2025
📈 PositiveBenzinga•Sep 8, 2025, 12:32 PM
Evolus Announces US Study Of Evolysse Sculpt Met Primary Endpoint Of Non-Inferiority And Showed Statistical Superiority To Restylane-Lyft
📈 PositiveBenzinga•Aug 25, 2025, 12:08 PM•Also:
Evolus Submits Final FDA PMA Module For Evolysse Sculpt Injectable HA Gel
📈 PositiveBenzinga•Aug 20, 2025, 12:04 PM
Evolus plunges after Q2 miss, guidance cut; Needham downgrades
📉 NegativeSeeking Alpha•Aug 6, 2025, 07:31 PM
Frequently Asked Questions about EOLS
What is EOLS's current stock price?
Evolus, Inc. (EOLS) is currently trading at $5.72 per share. The stock has moved -0.78% today.
What is the analyst price target for EOLS?
The average analyst price target for EOLS is $18.00, based on 1 analyst.
What sector is Evolus, Inc. in?
Evolus, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is EOLS's market cap?
Evolus, Inc. has a market capitalization of $0.37 billion, making it a small-cap company.
Does EOLS pay dividends?
No, Evolus, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAUTL
Autolus Therapeutics plc
$1.37
Mkt Cap: $0.4B
CBLL
CeriBell, Inc.
$22.79
Mkt Cap: $0.8B
EHAB
Enhabit, Inc.
$10.95
Mkt Cap: $0.6B
KIDS
OrthoPediatrics Corp.
$18.69
Mkt Cap: $0.5B
KMDA
Kamada Ltd.
$7.88
Mkt Cap: $0.5B
NGNE
Neurogene Inc.
$16.95
Mkt Cap: $0.3B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
SLDB
Solid Biosciences Inc.
$5.16
Mkt Cap: $0.4B
TMCI
Treace Medical Concepts, Inc.
$2.71
Mkt Cap: $0.2B
TOI
The Oncology Institute, Inc.
$3.53
Mkt Cap: $0.3B
Explore stocks similar to EOLS for comparison